Ondansetron Syri Pharma

Ondansetron, the active ingredient in Ondansetron Syri Pharma, is a 5‑HT3 receptor antagonist presented as a strength/form for oral use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and paediatric patients.

GNH USA supplies Ondansetron Syri Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways. - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: helps control nausea during and after radiation treatment. - Post‑operative nausea and vomiting: lowers the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑associated nausea (hyperemesis gravidarum): provides symptomatic relief when other measures are insufficient.

Adverse reactions to ondansetron are generally dose‑related and may vary in frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel motility. - Diarrhoea: occasional loose stools. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headedness. - Injection site pain (if administered parenterally).

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with rapid IV administration. - Severe hypersensitivity: rash, pruritus, angio‑oedema or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Severe constipation or paralytic ileus. - Neuro‑muscular weakness: rare neuromuscular complications.

When prescribing ondansetron, clinicians should consider patient‑specific factors and monitor for known safety concerns. - Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte abnormalities. - Concomitant serotonergic drugs: avoid or use with caution to reduce serotonin syndrome risk. - Electrolyte imbalance: correct hypokalaemia or hypomagnesaemia before initiation. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgement. - Store at below 25 °C: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medication classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic agents (e.g., quinidine, amiodarone): may increase QT‑interval prolongation risk.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): monitor for signs of serotonin syndrome. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): modestly increase exposure. - Diuretics causing electrolyte loss: monitor electrolytes to reduce arrhythmia risk.